menu
    • menu

    Company profile for Relmada Therapeutics

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Relmada Therapeutics, Inc. is a clinical stage, publicly traded biotechnology company, developing dextromethadone (REL-1017) as a rapid-acting oral treatment for depression, CNS and ophthalmological disorders. We are a clinical stage, publicly traded specialty pharmaceutical company, focused on developing dextromethadone (REL-1017) as a rapid-acting oral treatment for depression, CNS and ophthalmological disorders. We leverage...
    Relmada Therapeutics, Inc. is a clinical stage, publicly traded biotechnology company, developing dextromethadone (REL-1017) as a rapid-acting oral treatment for depression, CNS and ophthalmological disorders. We are a clinical stage, publicly traded specialty pharmaceutical company, focused on developing dextromethadone (REL-1017) as a rapid-acting oral treatment for depression, CNS and ophthalmological disorders. We leverage our considerable industry and development experience, and disease knowledge to identify, develop and commercialize product candidates for CNS conditions with high unmet needs.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Relmada TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Relmada Therapeutics, Inc. 880 Third Avenue 12th Floor New York, NY 10022
    Telephone
    Telephone
    646-876-3459
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.relmada.com/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/relmada-therapeutics-inc
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/relmada?lang=en

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Relmada Therapeutics Presents NDV-01 Phase 2 Data at SUO
    Relmada Therapeutics Presents NDV-01 Phase 2 Data at SUO

    03 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/03/3198765/0/en/Relmada-Therapeutics-Announces-Presentation-of-NDV-01-Phase-2-Data-at-the-Society-for-Urologic-Oncology.html

    GLOBENEWSWIRE
    03 Dec 2025
    Share Share
    Relmada Therapeutics Unveils Q3 2025 Financials And Vital Updates
    Relmada Therapeutics Unveils Q3 2025 Financials And Vital Updates

    13 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/13/3187806/0/en/Relmada-Therapeutics-Reports-Third-Quarter-2025-Financial-Results-and-Provides-Key-Clinical-Regulatory-and-Corporate-Updates.html

    GLOBENEWSWIRE
    13 Nov 2025
    Share Share
    FDA Approves Relmada's NDV-01 for 92% Bladder Cancer Response
    FDA Approves Relmada's NDV-01 for 92% Bladder Cancer Response

    10 Nov 2025

    // INDPHARMAPOST

    https://www.indianpharmapost.com/clinical-trials/relmada-gains-fda-backing-for-two-registrational-trials-and-reports-92-response-with-ndv-01-in-bladder-cancer-18197

    INDPHARMAPOST
    10 Nov 2025
    Share Share
    Relmada Therapeutics To Release Q3 2025 Financial Results
    Relmada Therapeutics To Release Q3 2025 Financial Results

    07 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/07/3183557/0/en/Relmada-Therapeutics-to-Report-Third-Quarter-2025-Financial-Results-on-Thursday-November-13-2025.html

    GLOBENEWSWIRE
    07 Nov 2025
    Share Share
    Relmada Pharma Prices $100M Stock Offering & Pre-Funded Warrants
    Relmada Pharma Prices $100M Stock Offering & Pre-Funded Warrants

    04 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/04/3180181/0/en/Relmada-Therapeutics-Announces-Pricing-of-100-Million-Underwritten-Offering-of-Common-Stock-and-Pre-Funded-Warrants.html

    GLOBENEWSWIRE
    04 Nov 2025
    Share Share
    Relmada Appoints Dr. Max Kates To Advance NDV-01 To Phase 3
    Relmada Appoints Dr. Max Kates To Advance NDV-01 To Phase 3

    13 Oct 2025

    // INDPHARMAPOST

    https://www.indianpharmapost.com/people/relmada-therapeutics-appoints-dr-max-kates-to-propel-ndv-01-toward-phase-3-17994

    INDPHARMAPOST
    13 Oct 2025
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search